|
7 Companies |
|
9 Products |
|
9 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
60 News |
|
| «12 |
- Kanuma (sebelipase alfa) / AstraZeneca
Trial termination: Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 (clinicaltrials.gov) - Jan 17, 2013
P2/3, N=10, Terminated, Sponsor: Synageva BioPharma Corp.
Enrolling by invitation --> Terminated; Study has been merged with NCT01371825
- miglustat / Generic mfg.
New P3 trial: Application of Miglustat in Patients With Niemann-Pick Type C (clinicaltrials.gov) - Jan 2, 2013
P3, N=5, Completed, Sponsor: National Taiwan University Hospital
- Clinical: Living With Frontotemporal Dementia (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=40, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
- Xenpozyme (olipudase alfa) / Sanofi
New P1 trial: Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients (clinicaltrials.gov) - Nov 5, 2012
P1, N=5, Completed, Sponsor: Genzyme, a Sanofi Company
- ||| Trial completion: Performance of AclarusDx (clinicaltrials.gov) - Jul 3, 2012
P=N/A, N=160, Completed, Sponsor: Exonhit
Enrolling by invitation --> Terminated; Study has been merged with NCT01371825 Recruiting --> Completed
- |||||||||| LMTX (hydromethylthionine) / TauRx
New P3 trial: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Jun 20, 2012
P3, N=180, Recruiting, Sponsor: TauRx Therapeutics Ltd
- || memantine / Generic mfg.
Trial completion, FDG PET: Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia (clinicaltrials.gov) - May 31, 2012
P3, N=17, Completed, Sponsor: Tiffany Chow, MD
Recruiting --> Completed Active, not recruiting --> Completed
- Kanuma (sebelipase alfa) / AstraZeneca
New P2/3 trial: Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 (clinicaltrials.gov) - Nov 15, 2011
P2/3, N=10, Terminated, Sponsor: Synageva BioPharma Corp.